Bartonellosis Therapeutics Market
Market Insights on Bartonellosis Therapeutics covering sales outlook, demand forecast & up-to-date key trends
Bartonellosis Therapeutics Market by Drug Class, Route of Administration, Distribution Channel, End Users, Region | Forecast 2023 to 2033
Bartonellosis Therapeutics Market Snapshot (2023 to 2033)
The global bartonellosis therapeutics market size is expected to surpass an impressive valuation of US$ 1.2 Billion in 2023 and is projected to exhibit a CAGR of 12% from 2023 to 2033, reaching US$ 3.72 Billion.
Bartonellosis is a bacterial infection caused by the genus Bartonella. Carrión's disease, trench fever, cat scratch illness, bacillary angiomatosis, peliosis hepatis, prolonged bacteremia, endocarditis, chronic lymphadenopathy, and neurological disorders are all induced by Bartonella species. Bartonella henselae is the most prevalent trigger of bartonellosis in the United States.
People who are homeless are more likely to become infected with B. Quintana because they have restricted access to shower and laundry amenities. Infection with B. Quintana occurs worldwide. As a result, this factor is propelling overall growth.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 1.2 Billion |
|
Anticipated Forecast Value (2033) |
US$ 3.72 Billion |
|
Projected Growth Rate (2023 to 2033) |
12% CAGR |
Let us know your requirement to get
100% FREE customization
2018 to 2022 Bartonellosis Therapeutics Demand Analysis vs. Forecast 2023 to 2033
The presence of a robust product pipeline, as well as upcoming launches propelled the market growth. One of the key determinants in the market is the rising Research and Development investments by prevalent vendors for orphan-developing drugs and innovative product offerings. In 2021, there were approximately 791 prospective orphan drug applicants in clinical trials for the treatment of rare diseases, as per Pharmaceutical Research and Manufacturers of America. As a result, the market for bartonellosis therapeutics grew during the historical era.
Over the forecast period the market for bartonellosis therapeutics is expected to grow because, without therapies, the fatality rate from this illness ranges from 40 to 90%. With the pathogen preserved in the body, bartonellosis enters a dormant stage, followed by reoccurrence and the evolution of a chronic phase, the Peruvian wart.
Which are Some Prominent Drivers of the Bartonellosis Therapeutics Market?
Development of More Effective Antibiotics to Generate Widespread Opportunities for Growth
Antibiotic demand is rapidly expanding owing to an increase in cat scratch disease cases and soaring market growth. The increased prevalence of the disease is captivating government bodies to spend on Research and Development approaches and fuel the creation of breakthrough antibiotics therapy, in addition to encouraging regulatory policies to accelerate the authorization and funding for research. For example, BARDA, in collaboration with the US government, has assisted several organizations in the development of novel treatments for bartonellosis.
The development of novel SMA Drugs to Drive Sales Growth
A multidisciplinary approach based on breakthrough proposals for the creation of novel SMA drugs to address unmet medical needs in rare therapeutic strategies is expected to drive market growth. In June 2021, for example, the European expert group on orphan drug incentives released a set of policy initiatives to address unmet healthcare needs in rare conditions.
This proposed policy involves a review of the EMA's pharma approach and orphan drug laws to encourage Spending on orphan drugs. In addition, basic research on patient access, new therapeutic challenges, and governmental authorizations are key areas highlighted in the proposed policies. During the forecast timeframe, such favorable government approaches are predicted to encourage market growth.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
A rise in Multidrug-Resistant Bacterial Infections may have a Restraining Influence on Market Expansion
Pharmaceutical companies are forming partnerships to develop new therapeutic strategies to minimize the financial strain of the process of drug development. However, an increase in multidrug-resistant bacterial infections may put a damper on the industry.
Region-Wise Insights
What Makes North America the Largest Market for Bartonellosis Therapeutics?
Increasing Number of CSD cases in the United States to drive Growth
North America's market is highly subject to regulation and has a robust healthcare system. The emergence of communicable disease cases and government health expenditures in the region is a significant factor propelling the market in North America. To regulate cat scratch diseases, the US government is implementing a variety of measures, including antibiotic stewardship initiatives and encouraging Research and development for therapeutic approaches.
The United States. Stray cats are more inclined to be infected with B. henselae than pets. The majority of CSD cases in the United States occur in the fall and winter. Thus it is expected to propel market growth in North America. According to Future Market Insights, the USA is likely to experience a CAGR of 11.7% with regard to bartonellosis therapeutics.
Why is Asia Pacific Considered a Lucrative Region for the Bartonellosis Therapeutics Market?
Government Initiatives to foster Orphan Drugs Development Programs to propel Growth
During the projected timeline, Asia Pacific is projected to be the fastest emerging market. The region's expansion can be attributed to government interventions to assist orphan disorder patients. For example, in July 2022, the Indian government oriented national and state governments to ensure the successful implementation of insurance programs created for the treatment of people undergoing orphan diseases.
This indicator offers an opportunity for healthcare practitioners to develop excellent quality orphan medications for the administration while also generating revenue. As a result, this factor is anticipated to propel the bartonellosis therapeutics market in the upcoming decade. FMI expects the APAC market for bartonellosis therapeutics to accumulate a revenue share of 33% in 2023.
What Makes Europe the Largest Market for Bartonellosis Therapeutics?
Europe to drive market owing to increased demand for Cutting-Edge Medical Services
Europe is expected to expand significantly during the projected timeframe, 2023-2033. The market's expansion can be mainly ascribed to the region's burgeoning demand for cutting-edge medical services, which is fueled by the region's population explosion in countries such as the United Kingdom, France, Germany, Sweden, the Netherlands, Italy, and Russia.
As per World Bank statistics, the total population in the United Kingdom and France in 2021 was 67,326,569, and 67,499,343, respectively. As a result, the Bartonellosis market is anticipated to grow further. A CAGR of 11.5% is projected for the bartonellosis therapeutics market in Europe.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
By End-User, Which Segment is Projected to Lead the Market?
Treatment for Bartonellosis to be Maximum across Hospitals
During the evaluation period, the hospital is expected to be the fastest-growing segment owing to the high hospitalization rate of SMA. As per the report, hospitals are likely to account for 40% of all bartonellosis therapeutics in 2023 and beyond.
Because of the high well construction and equipment facilities, hospitals treat the vast bulk of bartonellosis patients. As a result, the hospital segment is anticipated to account for a sizable share of the market.
Which Segment under Drug Class Will Account for the Highest Market Growth?
Demand for Antibiotics to be at the Pinnacle
Infectious diseases are always treated with antibiotics and medications. Given the possibility of supplementary salmonellosis, ciprofloxacin or chloramphenicol should be used in conjunction with a beta-lactam antibiotic to cure the disease swiftly.
As a result, the demand for antibiotics medicine is rapidly increasing, propelling the segment's growth, and expected to capture a revenue share of over 50% in 2023 and beyond.
Start-ups offering Therapeutics for Bartonellosis
- Galaxy Diagnostics, established in 2007, is an initial infectious disease diagnostic company. Galaxy Diagnostics began testing on animals in 2009 and human testing in 2011 and has improved testing methodologies over the years. The company provides Bartonella tests for cats and dogs, and the tests are also obtainable through a collaboration with Idexx Laboratories.
Market Competition
Key players in the Bartonellosis Therapeutics market are Abbott, Allergan, Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., Novartis AG, Sanofi, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Viatris, Sun Pharmaceutical Industries Ltd., Lilly, Aurobindo Pharma, Lupin, AstraZeneca, Johnson & Johnson Private Limited, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Bristol-Myers Squibb Company.
- Bayer Healthcare Animal Health has been working with veterinarians, physicians, and specialists on bartonellosis diseases all over the world. In addition, Bayer Animal Health provides products such as Seresto, which protects pets from fleas and prevents bartonellosis. This is the latest in a series of innovative anti-parasite product lines from one of the world's foremost animal medical companies.
- In July 2021, GlaxoSmithKline Plc. collaborated with Alector to develop and commercialize two clinical-stage, potential first-in-class monoclonal antibodies named AL001 and AL101. These antibodies are designed to evaluate progranulin levels, a key regulator of immune activity in the brain assisting in managing neurodegenerative disorders. The collaboration brings together Alector’s leading immuno-neurology expertise with GSK’s Research and Development focus on the science of the immune system and human genetics, proven late-stage drug development capabilities, and global footprint.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 1.2 Billion |
|
Market Value in 2033 |
US$ 3.72 Billion |
|
Growth Rate |
CAGR of 12% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Bartonellosis Therapeutics Market Industry Survey
By Drug Class:
- Antibiotics
- NSAIDs
- Others
By Route of Administration:
- Oral
- Intravenous
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By End Users:
- Hospitals
- Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Frequently Asked Questions
According to Future Market Insights, the bartonellosis treatment market is expected to be valued at US$ 1.2 Billion in 2023
From 2023 to 2033, bartonellosis treatment worth is expected to grow at a CAGR of 12%
As per the report, what is the expected closing value of the bartonellosis treatment market in 2033?
As of 2033, the bartonellosis treatment market is likely to reach US$ 3.72 Billion
The bartonellosis therapeutics landscape in the U.S is expected to grow at an 11.7% CAGR from 2023-2033
In the Asia Pacific, bartonellosis therapeutics is expected to account for 1/3rd of all bacterial infections treatment in 2023
Europe is most likely to experience a growth rate of 11.5% with regard to bartonellosis therapeutics from 2023-2033
Antibiotics are expected to constitute 50% of all bartonellosis treatments
GlaxoSmithKline Plc., Abbott Laboratories, Sanofi SA and Pfizer Inc. are some key bartonellosis therapeutics providers
Table of Content
1. Executive Summary | Bartonellosis Therapeutics Market
1.1. Global Market Outlook
1.2. Demand to side Trends
1.3. Supply to side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023 to 2033
4.2.1. Y to o to Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Antibiotics
5.3.2. NSAIDs
5.3.3. Others
5.4. Y to o to Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Intravenous
6.3.3. Others
6.4. Y to o to Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Y to o to Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End to Users
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Mn) Analysis By End to Users, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End to Users, 2023 to 2033
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Others
8.4. Y to o to Y Growth Trend Analysis By End to Users, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End to Users, 2023 to 2033
9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By End to Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.3.5. By End to Users
10.4. Key Takeaways
11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.2.5. By End to Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.3.5. By End to Users
11.4. Key Takeaways
12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.2.5. By End to Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.3.5. By End to Users
12.4. Key Takeaways
13. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.1.4. Singapore
13.2.1.5. Thailand
13.2.1.6. Indonesia
13.2.1.7. Australia
13.2.1.8. New Zealand
13.2.1.9. Rest of Asia Pacific
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.2.5. By End to Users
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.3.5. By End to Users
13.4. Key Takeaways
14. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.2.5. By End to Users
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.3.5. By End to Users
14.4. Key Takeaways
15. Key Countries Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug Class
15.1.2.2. By Route of Administration
15.1.2.3. By Distribution Channel
15.1.2.4. By End to Users
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug Class
15.2.2.2. By Route of Administration
15.2.2.3. By Distribution Channel
15.2.2.4. By End to Users
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug Class
15.3.2.2. By Route of Administration
15.3.2.3. By Distribution Channel
15.3.2.4. By End to Users
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug Class
15.4.2.2. By Route of Administration
15.4.2.3. By Distribution Channel
15.4.2.4. By End to Users
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug Class
15.5.2.2. By Route of Administration
15.5.2.3. By Distribution Channel
15.5.2.4. By End to Users
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug Class
15.6.2.2. By Route of Administration
15.6.2.3. By Distribution Channel
15.6.2.4. By End to Users
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug Class
15.7.2.2. By Route of Administration
15.7.2.3. By Distribution Channel
15.7.2.4. By End to Users
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug Class
15.8.2.2. By Route of Administration
15.8.2.3. By Distribution Channel
15.8.2.4. By End to Users
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug Class
15.9.2.2. By Route of Administration
15.9.2.3. By Distribution Channel
15.9.2.4. By End to Users
15.10. China
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug Class
15.10.2.2. By Route of Administration
15.10.2.3. By Distribution Channel
15.10.2.4. By End to Users
15.11. Japan
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug Class
15.11.2.2. By Route of Administration
15.11.2.3. By Distribution Channel
15.11.2.4. By End to Users
15.12. South Korea
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug Class
15.12.2.2. By Route of Administration
15.12.2.3. By Distribution Channel
15.12.2.4. By End to Users
15.13. Singapore
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug Class
15.13.2.2. By Route of Administration
15.13.2.3. By Distribution Channel
15.13.2.4. By End to Users
15.14. Thailand
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug Class
15.14.2.2. By Route of Administration
15.14.2.3. By Distribution Channel
15.14.2.4. By End to Users
15.15. Indonesia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug Class
15.15.2.2. By Route of Administration
15.15.2.3. By Distribution Channel
15.15.2.4. By End to Users
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug Class
15.16.2.2. By Route of Administration
15.16.2.3. By Distribution Channel
15.16.2.4. By End to Users
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug Class
15.17.2.2. By Route of Administration
15.17.2.3. By Distribution Channel
15.17.2.4. By End to Users
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug Class
15.18.2.2. By Route of Administration
15.18.2.3. By Distribution Channel
15.18.2.4. By End to Users
15.19. South Africa
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug Class
15.19.2.2. By Route of Administration
15.19.2.3. By Distribution Channel
15.19.2.4. By End to Users
15.20. Israel
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug Class
15.20.2.2. By Route of Administration
15.20.2.3. By Distribution Channel
15.20.2.4. By End to Users
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Route of Administration
16.3.4. By Distribution Channel
16.3.5. By End to Users
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Abbott
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Allergan
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. F. Hoffmann to La Roche Ltd.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. GlaxoSmithKline plc
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Merck Sharp & Dohme Corp.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Novartis AG
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Sanofi
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Pfizer Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Teva Pharmaceutical Industries Ltd.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Bayer AG
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Viatris
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Sun Pharmaceutical Industries Ltd.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Lilly
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. Aurobindo Pharma
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.15. Lupin
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
17.1.16. AstraZeneca
17.1.16.1. Overview
17.1.16.2. Product Portfolio
17.1.16.3. Profitability by Market Segments
17.1.16.4. Sales Footprint
17.1.16.5. Strategy Overview
17.1.16.5.1. Marketing Strategy
17.1.17. Johnson & Johnson Private Limited
17.1.17.1. Overview
17.1.17.2. Product Portfolio
17.1.17.3. Profitability by Market Segments
17.1.17.4. Sales Footprint
17.1.17.5. Strategy Overview
17.1.17.5.1. Marketing Strategy
17.1.18. Boehringer Ingelheim International GmbH
17.1.18.1. Overview
17.1.18.2. Product Portfolio
17.1.18.3. Profitability by Market Segments
17.1.18.4. Sales Footprint
17.1.18.5. Strategy Overview
17.1.18.5.1. Marketing Strategy
17.1.19. Dr. Reddy’s Laboratories Ltd.,
17.1.19.1. Overview
17.1.19.2. Product Portfolio
17.1.19.3. Profitability by Market Segments
17.1.19.4. Sales Footprint
17.1.19.5. Strategy Overview
17.1.19.5.1. Marketing Strategy
17.1.20. Bristol to Myers Squibb Company
17.1.20.1. Overview
17.1.20.2. Product Portfolio
17.1.20.3. Profitability by Market Segments
17.1.20.4. Sales Footprint
17.1.20.5. Strategy Overview
17.1.20.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Value (US$ Mn) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Mn) Forecast by Drug Class, 2018 to 2033
Table 3: Global Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 5: Global Value (US$ Mn) Forecast by End to Users, 2018 to 2033
Table 6: North America Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 7: North America Value (US$ Mn) Forecast by Drug Class, 2018 to 2033
Table 8: North America Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033
Table 9: North America Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 10: North America Value (US$ Mn) Forecast by End to Users, 2018 to 2033
Table 11: Latin America Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 12: Latin America Value (US$ Mn) Forecast by Drug Class, 2018 to 2033
Table 13: Latin America Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033
Table 14: Latin America Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 15: Latin America Value (US$ Mn) Forecast by End to Users, 2018 to 2033
Table 16: Europe Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 17: Europe Value (US$ Mn) Forecast by Drug Class, 2018 to 2033
Table 18: Europe Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033
Table 19: Europe Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 20: Europe Value (US$ Mn) Forecast by End to Users, 2018 to 2033
Table 21: Asia Pacific Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 22: Asia Pacific Value (US$ Mn) Forecast by Drug Class, 2018 to 2033
Table 23: Asia Pacific Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033
Table 24: Asia Pacific Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 25: Asia Pacific Value (US$ Mn) Forecast by End to Users, 2018 to 2033
Table 26: MEA Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 27: MEA Value (US$ Mn) Forecast by Drug Class, 2018 to 2033
Table 28: MEA Value (US$ Mn) Forecast by Route of Administration, 2018 to 2033
Table 29: MEA Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 30: MEA Value (US$ Mn) Forecast by End to Users, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Value (US$ Mn) by Drug Class, 2023 to 2033
Figure 2: Global Value (US$ Mn) by Route of Administration, 2023 to 2033
Figure 3: Global Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 4: Global Value (US$ Mn) by End to Users, 2023 to 2033
Figure 5: Global Value (US$ Mn) by Region, 2023 to 2033
Figure 6: Global Value (US$ Mn) Analysis by Region, 2018 to 2033
Figure 7: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Y to o to Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Value (US$ Mn) Analysis by Drug Class, 2018 to 2033
Figure 10: Global Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 11: Global Y to o to Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 12: Global Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033
Figure 13: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 14: Global Y to o to Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 15: Global Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 16: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 17: Global Y to o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 18: Global Value (US$ Mn) Analysis by End to Users, 2018 to 2033
Figure 19: Global Value Share (%) and BPS Analysis by End to Users, 2023 to 2033
Figure 20: Global Y to o to Y Growth (%) Projections by End to Users, 2023 to 2033
Figure 21: Global Attractiveness by Drug Class, 2023 to 2033
Figure 22: Global Attractiveness by Route of Administration, 2023 to 2033
Figure 23: Global Attractiveness by Distribution Channel, 2023 to 2033
Figure 24: Global Attractiveness by End to Users, 2023 to 2033
Figure 25: Global Attractiveness by Region, 2023 to 2033
Figure 26: North America Value (US$ Mn) by Drug Class, 2023 to 2033
Figure 27: North America Value (US$ Mn) by Route of Administration, 2023 to 2033
Figure 28: North America Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 29: North America Value (US$ Mn) by End to Users, 2023 to 2033
Figure 30: North America Value (US$ Mn) by Country, 2023 to 2033
Figure 31: North America Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Y o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Value (US$ Mn) Analysis by Drug Class, 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 36: North America Y o to Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 37: North America Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033
Figure 38: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 39: North America Y o to Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 40: North America Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 41: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: North America Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: North America Value (US$ Mn) Analysis by End to Users, 2018 to 2033
Figure 44: North America Value Share (%) and BPS Analysis by End to Users, 2023 to 2033
Figure 45: North America Y o to Y Growth (%) Projections by End to Users, 2023 to 2033
Figure 46: North America Attractiveness by Drug Class, 2023 to 2033
Figure 47: North America Attractiveness by Route of Administration, 2023 to 2033
Figure 48: North America Attractiveness by Distribution Channel, 2023 to 2033
Figure 49: North America Attractiveness by End to Users, 2023 to 2033
Figure 50: North America Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Value (US$ Mn) by Drug Class, 2023 to 2033
Figure 52: Latin America Value (US$ Mn) by Route of Administration, 2023 to 2033
Figure 53: Latin America Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 54: Latin America Value (US$ Mn) by End to Users, 2023 to 2033
Figure 55: Latin America Value (US$ Mn) by Country, 2023 to 2033
Figure 56: Latin America Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 57: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Y o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Value (US$ Mn) Analysis by Drug Class, 2018 to 2033
Figure 60: Latin America Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 61: Latin America Y o to Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 62: Latin America Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033
Figure 63: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 64: Latin America Y to o to Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 65: Latin America Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 66: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 67: Latin America Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 68: Latin America Value (US$ Mn) Analysis by End to Users, 2018 to 2033
Figure 69: Latin America Value Share (%) and BPS Analysis by End to Users, 2023 to 2033
Figure 70: Latin America Y o to Y Growth (%) Projections by End to Users, 2023 to 2033
Figure 71: Latin America Attractiveness by Drug Class, 2023 to 2033
Figure 72: Latin America Attractiveness by Route of Administration, 2023 to 2033
Figure 73: Latin America Attractiveness by Distribution Channel, 2023 to 2033
Figure 74: Latin America Attractiveness by End to Users, 2023 to 2033
Figure 75: Latin America Attractiveness by Country, 2023 to 2033
Figure 76: Europe Value (US$ Mn) by Drug Class, 2023 to 2033
Figure 77: Europe Value (US$ Mn) by Route of Administration, 2023 to 2033
Figure 78: Europe Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 79: Europe Value (US$ Mn) by End to Users, 2023 to 2033
Figure 80: Europe Value (US$ Mn) by Country, 2023 to 2033
Figure 81: Europe Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 82: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Y to o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Value (US$ Mn) Analysis by Drug Class, 2018 to 2033
Figure 85: Europe Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 86: Europe Y to o to Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 87: Europe Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033
Figure 88: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 89: Europe Y to o to Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 90: Europe Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 91: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 92: Europe Y to o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 93: Europe Value (US$ Mn) Analysis by End to Users, 2018 to 2033
Figure 94: Europe Value Share (%) and BPS Analysis by End to Users, 2023 to 2033
Figure 95: Europe Y to o to Y Growth (%) Projections by End to Users, 2023 to 2033
Figure 96: Europe Attractiveness by Drug Class, 2023 to 2033
Figure 97: Europe Attractiveness by Route of Administration, 2023 to 2033
Figure 98: Europe Attractiveness by Distribution Channel, 2023 to 2033
Figure 99: Europe Attractiveness by End to Users, 2023 to 2033
Figure 100: Europe Attractiveness by Country, 2023 to 2033
Figure 101: Asia Pacific Value (US$ Mn) by Drug Class, 2023 to 2033
Figure 102: Asia Pacific Value (US$ Mn) by Route of Administration, 2023 to 2033
Figure 103: Asia Pacific Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 104: Asia Pacific Value (US$ Mn) by End to Users, 2023 to 2033
Figure 105: Asia Pacific Value (US$ Mn) by Country, 2023 to 2033
Figure 106: Asia Pacific Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 107: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: Asia Pacific Y o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: Asia Pacific Value (US$ Mn) Analysis by Drug Class, 2018 to 2033
Figure 110: Asia Pacific Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 111: Asia Pacific Y o to Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 112: Asia Pacific Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033
Figure 113: Asia Pacific Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 114: Asia Pacific Y o to Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 115: Asia Pacific Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 116: Asia Pacific Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 117: Asia Pacific Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 118: Asia Pacific Value (US$ Mn) Analysis by End to Users, 2018 to 2033
Figure 119: Asia Pacific Value Share (%) and BPS Analysis by End to Users, 2023 to 2033
Figure 120: Asia Pacific Y o to Y Growth (%) Projections by End to Users, 2023 to 2033
Figure 121: Asia Pacific Attractiveness by Drug Class, 2023 to 2033
Figure 122: Asia Pacific Attractiveness by Route of Administration, 2023 to 2033
Figure 123: Asia Pacific Attractiveness by Distribution Channel, 2023 to 2033
Figure 124: Asia Pacific Attractiveness by End to Users, 2023 to 2033
Figure 125: Asia Pacific Attractiveness by Country, 2023 to 2033
Figure 126: MEA Value (US$ Mn) by Drug Class, 2023 to 2033
Figure 127: MEA Value (US$ Mn) by Route of Administration, 2023 to 2033
Figure 128: MEA Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 129: MEA Value (US$ Mn) by End to Users, 2023 to 2033
Figure 130: MEA Value (US$ Mn) by Country, 2023 to 2033
Figure 131: MEA Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 132: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: MEA Y o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: MEA Value (US$ Mn) Analysis by Drug Class, 2018 to 2033
Figure 135: MEA Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 136: MEA Y to o to Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 137: MEA Value (US$ Mn) Analysis by Route of Administration, 2018 to 2033
Figure 138: MEA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 139: MEA Y o to Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 140: MEA Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 141: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 142: MEA Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 143: MEA Value (US$ Mn) Analysis by End to Users, 2018 to 2033
Figure 144: MEA Value Share (%) and BPS Analysis by End to Users, 2023 to 2033
Figure 145: MEA Y o to Y Growth (%) Projections by End to Users, 2023 to 2033
Figure 146: MEA Attractiveness by Drug Class, 2023 to 2033
Figure 147: MEA Attractiveness by Route of Administration, 2023 to 2033
Figure 148: MEA Attractiveness by Distribution Channel, 2023 to 2033
Figure 149: MEA Attractiveness by End to Users, 2023 to 2033
Figure 150: MEA Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
